- Home
- BGLC vs KTTA Comparison
BGLC vs KTTA Comparison
Compare BGLC & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- KTTA
- Stock Information
- Founded
- BGLC 2017
- KTTA 2020
- Country
- BGLC Malaysia
- KTTA United States
- Employees
- BGLC N/A
- KTTA N/A
- Industry
- BGLC Medical Specialities
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- KTTA Health Care
- Exchange
- BGLC Nasdaq
- KTTA Nasdaq
- Market Cap
- BGLC 5.0M
- KTTA 5.5M
- IPO Year
- BGLC N/A
- KTTA 2021
- Fundamental
- Price
- BGLC $6.41
- KTTA $0.73
- Analyst Decision
- BGLC
- KTTA
- Analyst Count
- BGLC 0
- KTTA 0
- Target Price
- BGLC N/A
- KTTA N/A
- AVG Volume (30 Days)
- BGLC 2.7M
- KTTA 166.4K
- Earning Date
- BGLC 08-13-2025
- KTTA 08-12-2025
- Dividend Yield
- BGLC N/A
- KTTA N/A
- EPS Growth
- BGLC N/A
- KTTA N/A
- EPS
- BGLC N/A
- KTTA N/A
- Revenue
- BGLC $9,265,870.00
- KTTA N/A
- Revenue This Year
- BGLC N/A
- KTTA N/A
- Revenue Next Year
- BGLC N/A
- KTTA N/A
- P/E Ratio
- BGLC N/A
- KTTA N/A
- Revenue Growth
- BGLC N/A
- KTTA N/A
- 52 Week Low
- BGLC $2.01
- KTTA $0.70
- 52 Week High
- BGLC $15.60
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- BGLC 60.18
- KTTA 36.47
- Support Level
- BGLC $5.56
- KTTA $0.70
- Resistance Level
- BGLC $15.60
- KTTA $0.76
- Average True Range (ATR)
- BGLC 0.96
- KTTA 0.04
- MACD
- BGLC 0.52
- KTTA 0.01
- Stochastic Oscillator
- BGLC 29.46
- KTTA 21.88
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).